Ligand Pharmaceuticals Incorporated Financials

Market Capitalization $2.21 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	46.27
Forward PE	19.16
Price to Sales TTM	$12.18
Price to Book MRQ	$2.78
Enterprise to Revenue	10.96
Enterprise to EBITDA	109.54

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	-73.07%
Operating Margin	-80.87%
Return on Assets TTM	-1.14%
Return on Equity TTM	-16.56%

Income Statement

Revenue TTM	$181,488,000
Revenue per Share TTM	$9.73
Quarterly Revenue Growth	46.30%
Gross Profit TTM	$102,908,000
EBITDA	$11,397,000
Net Income to Common TTM	$-132,622,000
Diluted EPS TTM	$-7.29
Quarterly Earnings Growth YoY	46.34%

Balance Sheet

Total Cash MRQ	$208,900,992
Total Cash per Share MRQ	$10.83
Total Debt MRQ	$
Total Debt to Equity MRQ	0.56
Current Ratio MRQ	5.27
Book Value per Share MRQ	$41.27

Cash Flow

Operating Cash Flow TTM	$52,870,000
Levered Free Cash Flow TTM	$63,347,876

LGND Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	19,106,000
Float Shares	18,861,593
Avg 10 Volume	152,520
Avg 30 Volume	None
Shares Short	1,154,068
Short Ratio	10.11
Short % of Shares	7.25%
% Held by Insiders	2.29%
% Held by Institutions	99.82%

Stock Price Summary

Beta	0.71
Fifty Two Week Low	$81.74
Fifty Two Week High	$129.90
Fifty Two Week Change	26.37%
Day 50 MA	$108.23
Day 200 MA	$110.52

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	2010-07-02
Last Split Factor
Last Split Date	2022-11-02